Neurosci Behav Physiol. 2010 Feb;40(2):149-55. doi: 10.1007/s11055-009-9244-1.
Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Litvinenko IV1, Odinak MM, Mogil'naya VI, Perstnev SV.
This study addresses the effects of 52 weeks of treatment with the NMDA glutamate receptor antagonist memantine on motor, cognitive, and mental disorders in patients with Parkinson's disease complicated by dementia, as compared with a control group of patients not treated with memantine. Patients of the experimental group (32 subjects) received memantine (20 mg/day), while patients in the control group continued on antiparkinsonism treatment alone. Cognitive, psychiatric, and motor symptoms were assessed before the study and then at the ends of weeks 12, 24, and 52, using clinical assessment, rating scales, and neuropsychological tests. Plasma homocysteine levels were measured by HPLC. Patients treated with memantine had better measures on the MMSE (p < 0.05), ADAS-cog (p < 0.05), clock drawing test (p < 0.05), and FAB (p < 0.01) as compared with the control group by the end of study week 24. Members of the group of patients with high homocysteine levels mounted significantly better responses with memantine treatment, as compared with patients of the control group with high homocysteine levels but not receiving memantine, at the ends of study weeks 24 and 52, in terms of all rating scales (UPDRS, MMSE, ADAS-cog, D-KEFS Verbal Fluency Test, FAB. NPI, and DAD, p < 0.05). By the end of week 52, significant changes in points scores on the NPI-12 scale from baseline were in favor of patients receiving memantine, this applying to the disinhibition (p = 0.006), irritability (p = 0.04), anxiety (p = 0.04), and hallucinations (p = 0.048) subscales. The presence of hyperhomocysteinemia may indicate faster progression of both motor and cognitive impairments in Parkinson's disease. Prolonged memantine treatment of patients with Parkinson's disease complicated by dementia leads to improvements in cognitive functions, stabilization of motor impairments, and decreases in the severity of mental disorders, especially in patients with hyperhomocysteinemia.
PMID: 20033305 [PubMed - indexed for MEDLINE]
Expert Opin Pharmacother. 2014 May; 15(7): 913–925.
Published online 2014 Mar 27. doi: 10.1517/14656566.2014.902446
Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
Yu Nakamura, † , 1 Shin Kitamura, 2 Akira Homma, 3 Kazuhito Shiosakai, 4 and Daiju Matsui 5
Author information ► Copyright and License information ►
The final analysis comprised 633 patients (318 receiving memantine and 315 placebo). Memantine produced better outcomes in terms of Severe Impairment Battery-Japanese version, Clinician’s Interview-Based Impression of Change plus-Japanese version, Behavioral Pathology in AD Rating Scale, and language scores, versus placebo. The overall incidence of adverse events and adverse reactions was similar between groups.
PLoS One. 2015; 10(4): e0123289.
Published online 2015 Apr 10. doi: 10.1371/journal.pone.0123289
Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Shinji Matsunaga,* Taro Kishi, and Nakao Iwata
Terence J Quinn, Academic Editor
Clin Interv Aging. 2009; 4: 367–377.
Published online 2009 Oct 12.
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Stuart J Thomas and George T Grossberg